VERTEX PHARMACEUTICALS INC / MA (VRTX) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	13.0B	12.1B	11.0B	9.9B	8.9B
Cost of Revenue	1.9B	1.8B	1.5B	1.3B	1.1B
Gross Profit	11.1B	10.3B	9.5B	8.6B	7.9B
Operating Expenses
R&D Expense	4.2B	3.8B	3.6B	3.2B	2.7B
SG&A Expense	2.4B	1.8B	1.5B	1.1B	944.7M
General & Admin Expense	844.1M	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	59.6M	—	4.6B	475.5M	(57.5M)
Total Operating Expenses	6.7B	5.5B	9.7B	4.8B	3.5B
Cost and Expenses	8.6B	7.3B	11.3B	6.0B	4.6B
Operating Income (EBIT)	4.4B	4.8B	(232.9M)	3.8B	4.3B
Non-Operating
Interest Income	475.7M	490.9M	598.1M	614.7M	144.6M
Interest Expense	39.3M	13.3M	30.6M	44.1M	54.8M
Net Interest Income	436.4M	477.6M	567.5M	570.6M	89.8M
Other Non-Op Income/Expense	360.8M	(117.5M)	481.4M	547.8M	(75.0M)
Non-Operating Income (excl Interest)	(400.1M)	104.2M	(512.0M)	(591.9M)	20.2M
EBT (Pre-Tax Income)	4.8B	4.6B	248.5M	4.4B	4.2B
Income Tax Expense	783.2M	690.0M	784.1M	760.2M	910.4M
Bottom Line
Net Income	4.0B	4.0B	(535.6M)	3.6B	3.3B
Earnings from Cont. Ops	4.0B	4.0B	(535.6M)	3.6B	3.3B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	4.0B	4.0B	(535.6M)	3.6B	3.3B
Per Share
Basic EPS	$15.66	$15.46	($2.08)	$14.05	$12.97
Diluted EPS	$15.54	$15.32	($2.08)	$13.89	$12.82
Revenue Per Share	$51.24	$47.22	$42.80	$38.30	$34.87
Shares
Basic Shares Outstanding	253.5M	255.7M	257.5M	257.7M	256.1M
Diluted Shares Outstanding	255.2M	258.0M	257.9M	260.5M	259.1M
Profitability Metrics
EBITDA	5.0B	4.9B	486.3M	4.6B	4.4B
D&A	168.1M	209.8M	207.2M	181.3M	148.3M
EBIT	4.8B	4.7B	279.1M	4.4B	4.3B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026